ImmunityBio nears finish line for ANKTIVA expansion in bladder cancer
ImmunityBio (NASDAQ:IBRX) is moving toward a significant label expansion for its first-in-class immunotherapy, ANKTIVA® (nogapendekin alfa inbakicept), following a pivotal Type B meeting with the U.S. Food and Drug Administration (FDA).











